BLAIV (INFUSION)POWDERPriority Review
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
EBANGA (ansuvimab) by Ridgeback Biotherapeutics is zaire ebolavirus glycoprotein-directed antibody interactions [moa]. Approved for zaire ebolavirus glycoprotein-directed antibody [epc]. First approved in 2020.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EBANGA (ansuvimab) is a monoclonal antibody targeting the Zaire ebolavirus glycoprotein, designed to neutralize the virus and reduce mortality in infected patients. It is administered intravenously as a lyophilized powder for reconstitution. This is a first-in-class therapeutic for a rare but high-mortality viral infection.
Peak
Peak-stage orphan asset with limited commercial scaling; team size likely focused on regulatory maintenance, outbreak response coordination, and rare disease operations.
Mechanism of Action
Zaire Ebolavirus Glycoprotein-directed Antibody Interactions
Pharmacologic Class:
Zaire Ebolavirus Glycoprotein-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
Ebola Virus Disease
Career Relevance
Working on EBANGA offers a unique career path focused on rare disease, outbreak response, and government/humanitarian procurement rather than traditional commercial oncology or primary care. This role emphasizes regulatory expertise, public health acumen, and crisis management over high-volume sales and marketing.
Regulatory Affairs Manager
Worked on EBANGA at Ridgeback Biotherapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.